Literature DB >> 15730403

Elevated immunoglobulin G antibodies to the proline-rich amino-terminal region of Epstein-Barr virus nuclear antigen-2 in sera from patients with systemic connective tissue diseases and from a subgroup of Sjögren's syndrome patients with pulmonary involvements.

M Yamazaki1, R Kitamura, S Kusano, H Eda, S Sato, M Okawa-Takatsuji, S Aotsuka, K Yanagi.   

Abstract

Associations of Epstein-Barr virus (EBV) and autoimmune diseases have been hypothesized. We have analysed IgG antibodies to EBV nuclear antigen (EBNA)-2 in sera from Japanese patients with autoimmune systemic connective tissue diseases (CTD), exemplified by systemic lupus erythematosus (SLE), primary Sjogren's syndrome (SS), rheumatoid arthritis (RA), systemic sclerosis (SSc) and secondary SS (classical CTDs complicated with SS). An enzyme-linked immunosorbent assay (ELISA) which uses glutathione-S-transferase polypeptides fused to EBV nuclear antigen (EBNA)-2 and EBNA-1 was developed. Ratios of IgG antibody reactivity to whole IgG concentrations of sera were calculated to normalize EBNA-2 and EBNA-1 antibody levels to the hypergammaglobulinaemia that occurs in CTD. The ELISA optical density OD(450) readings of IgG antibodies to both the amino-terminal aa 1-116 of EBNA-2 and carboxyl-terminal aa 451-641 of EBNA-1 were elevated significantly in patients with SLE, primary SS, RA, SSc and secondary SS when compared to EBNA-1. The OD readings were divided by serum IgG concentrations to normalize for the hypergammaglobulinaemia. The specific levels of IgG antibodies to the amino-terminal region of EBNA-2 were elevated in patients with SLE, primary SS or RA, as well as those with secondary SS complicated with SLE or RA. The EBNA-2 amino-terminal region contains a polyproline tract and a proline-rich sequence and has considerable amino acid sequence homology with many cellular proline-rich proteins. High ratios of EBNA-2 aa 1-116 to EBNA-1 aa 451-641 IgG antibody levels which probably suggest reactivation of EBV latent infection were associated significantly with pulmonary involvement in SS patients. These results are consistent with the hypothesis that the sequence similarity between the amino-terminal region of EBNA-2 and proline-rich cellular proteins is associated with pathogenesis in a subpopulation of CTD patients, possibly by the molecular mimicry-epitope shift mechanism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15730403      PMCID: PMC1809310          DOI: 10.1111/j.1365-2249.2004.02704.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  64 in total

Review 1.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-01-15       Impact factor: 21.405

Review 2.  Epitope spreading in immune-mediated diseases: implications for immunotherapy.

Authors:  Carol L Vanderlugt; Stephen D Miller
Journal:  Nat Rev Immunol       Date:  2002-02       Impact factor: 53.106

3.  Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure.

Authors:  J A James; B R Neas; K L Moser; T Hall; G R Bruner; A L Sestak; J B Harley
Journal:  Arthritis Rheum       Date:  2001-05

4.  Antibodies to type II collagen and HLA disease susceptibility markers in rheumatoid arthritis.

Authors:  A D Cook; A Stockman; C A Brand; B D Tait; I R Mackay; K D Muirden; C C Bernard; M J Rowley
Journal:  Arthritis Rheum       Date:  1999-12

Review 5.  Virus-induced autoimmunity: epitope spreading to myelin autoepitopes in Theiler's virus infection of the central nervous system.

Authors:  S D Miller; Y Katz-Levy; K L Neville; C L Vanderlugt
Journal:  Adv Virus Res       Date:  2001       Impact factor: 9.937

6.  Epstein-Barr virus infection in peripheral blood mononuclear cells, synovial fluid cells, and synovial membranes of patients with rheumatoid arthritis.

Authors:  S Blaschke; G Schwarz; D Moneke; L Binder; G Müller; M Reuss-Borst
Journal:  J Rheumatol       Date:  2000-04       Impact factor: 4.666

Review 7.  Epitope spreading: a mechanism for progression of autoimmune disease.

Authors:  V K Tuohy; R P Kinkel
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2000       Impact factor: 4.291

8.  A population of autoantibodies against a centromere-associated protein A major epitope motif cross-reacts with related cryptic epitopes on other nuclear autoantigens and on the Epstein-Barr nuclear antigen 1.

Authors:  M Mahler; R Mierau; W Schlumberger; M Blüthner
Journal:  J Mol Med (Berl)       Date:  2001-07-25       Impact factor: 4.599

9.  Altered immune response to glycine-rich sequences of Epstein-Barr nuclear antigen-1 in patients with rheumatoid arthritis and systemic lupus erythematosus.

Authors:  J Petersen; G Rhodes; J Roudier; J H Vaughan
Journal:  Arthritis Rheum       Date:  1990-07

Review 10.  Collaborative research into outcome measures in Sjögren's syndrome. Update on disease assessment.

Authors:  S J Bowman
Journal:  Scand J Rheumatol Suppl       Date:  2002
View more
  12 in total

Review 1.  Xerostomia secondary to Sjögren's syndrome in the elderly: recognition and management.

Authors:  Ibtisam Al-Hashimi
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

2.  Nuclear import of Epstein-Barr virus nuclear antigen 1 mediated by NPI-1 (Importin alpha5) is up- and down-regulated by phosphorylation of the nuclear localization signal for which Lys379 and Arg380 are essential.

Authors:  Ryo Kitamura; Toshihiro Sekimoto; Sayuri Ito; Shizuko Harada; Hideo Yamagata; Hisao Masai; Yoshihiro Yoneda; Kazuo Yanagi
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 3.  The contribution of natural selection to present-day susceptibility to chronic inflammatory and autoimmune disease.

Authors:  Jessica F Brinkworth; Luis B Barreiro
Journal:  Curr Opin Immunol       Date:  2014-10-22       Impact factor: 7.486

Review 4.  Innate immunity in Sjögren's syndrome.

Authors:  Jeremy Kiripolsky; Liam G McCabe; Jill M Kramer
Journal:  Clin Immunol       Date:  2017-04-08       Impact factor: 3.969

5.  Aberrant Epstein-Barr viral infection in systemic lupus erythematosus.

Authors:  Brian D Poole; Amanda K Templeton; Joel M Guthridge; Eric J Brown; John B Harley; Judith A James
Journal:  Autoimmun Rev       Date:  2009-01-22       Impact factor: 9.754

6.  Immune complexome analysis reveals the presence of immune complexes and identifies disease-specific immune complex antigens in saliva samples from patients with Sjögren's syndrome.

Authors:  K Yamane; H Nakamura; M Hamasaki; Y Minei; N Aibara; T Shimizu; A Kawakami; M Nakashima; N Kuroda; K Ohyama
Journal:  Clin Exp Immunol       Date:  2021-02-22       Impact factor: 4.330

Review 7.  Epstein-Barr virus and rheumatoid arthritis: is there a link?

Authors:  Karen H Costenbader; Elizabeth W Karlson
Journal:  Arthritis Res Ther       Date:  2006-01-16       Impact factor: 5.156

8.  Toll-like receptor 7 stimulates the expression of Epstein-Barr virus latent membrane protein 1.

Authors:  Robert M Valente; Erica Ehlers; Dongsheng Xu; Humera Ahmad; Andrew Steadman; Laura Blasnitz; You Zhou; Lisa Kastanek; Bin Meng; Luwen Zhang
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

9.  E2 multimeric scaffold for vaccine formulation: immune response by intranasal delivery and transcriptome profile of E2-pulsed dendritic cells.

Authors:  Maria Trovato; Francesco Maurano; Luciana D'Apice; Valerio Costa; Rossella Sartorius; Fausta Cuccaro; Sean P McBurney; Shelly J Krebs; Antonella Prisco; Alfredo Ciccodicola; Mauro Rossi; Nancy L Haigwood; Piergiuseppe De Berardinis
Journal:  BMC Microbiol       Date:  2016-07-16       Impact factor: 3.605

Review 10.  Infections and autoimmunity: a panorama.

Authors:  V Pordeus; M Szyper-Kravitz; R A Levy; N M Vaz; Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.